Xiong Y, Zhang Y, Mahmood A, Chopp M
It refers to retatrutide, a tripleagonist weightloss medication that activates GLP1, GIP, and glucagon receptors. Early clinical trials show unprecedented weightloss results, often greater than currently approved GLP1 and dualagonist drugs, along with improvements in liver fat and metabolic markers. As research advances and more data become available, medically supervised programs will continue to evaluate where TRIPLEagonist medications fit among GLP1 drugs, dualagonists, peptides, and other tools for sustainable metabolic health
Priority Meds has its own pharmacy network
Rashad WA, Saadawy SF, Refaay NE (2023) Mitigating effect of L-carnitine against atrazine-induced hepatotoxicity: histopathological and biochemical analyses in albino rats
Endocrinology 146 (12), 51205127 (2005)
Its a time to raise awareness about heart disease, which